Ezequiel J. Molina

Ezequiel J. Molina

Auto-generated profile, based on publicly available information

Ezequiel J. Molina

Department of Cardiac Surgery, Piedmont Heart Institute, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
SASaima Aslam
Saima Aslam
JCJennifer Cowger
Jennifer Cowger
PSPalak Shah
Palak Shah
VSValentina Stosor
Valentina Stosor
HCHannah Copeland
Hannah Copeland
EMEzequiel Molina
Ezequiel Molina

24 June 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
ABAlexander M. Bernhardt
Alexander M. Bernhardt
VBVanessa Blumer
Vanessa Blumer
CVChristophe Vandenbriele
Christophe Vandenbriele
BSBenedikt Schrage
Benedikt Schrage
KMKanika Mody
Kanika Mody
MKManreet Kanwar
Manreet Kanwar
The Impella 5.5 (Abiomed, USA) is a catheter-based micro-axial flow pump that has emerged as a vital tool in managing patients with cardiogenic shock (CS). Delivering up to 5.5 L/min of flow, it enables full left ventricular (LV) support with beneficial hemodynamic and metabolic effects. Its unique advantages include high-flow, antegrade circulatory support with the potential for prolonged usage, making it suitable for bridging to recovery or heart replacement therapies. This manuscript provides a comprehensive, structured guide for the clinical management of patients supported with the Impella 5.5. It outlines best practices for patient selection, surgical implantation techniques-most commonly via the axillary artery-perioperative management, anticoagulation strategies, and postoperative monitoring. Special emphasis is placed on complication management, including bleeding, hemolysis, right ventricular dysfunction, stroke, aortic valve injury, and vascular complications. Technologies like SmartAssist and Impella Connect are highlighted for their utility in real-time device monitoring and remote management. The manuscript also discusses a three-phase framework for recovery: hemodynamic stabilization, initiation of guideline-directed medical therapy (GDMT), and structured weaning protocols. Considerations for transitioning patients to heart transplantation or durable LVADs, as well as explant techniques, are detailed. The importance of multidisciplinary coordination-including a mechanical circulatory support (MCS) coordinator-is emphasized to ensure optimal patient outcomes. By synthesizing available evidence and institutional experience, this guide aims to standardize Impella 5.5 management, reduce complications, and improve outcomes in critically ill patients with advanced heart failure or CS.

15 July 2024 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DGDaniel J. Goldstein
Daniel J. Goldstein
MKManreet Kanwar
Manreet Kanwar
JCJennifer Cowger
Jennifer Cowger
SPSnehal Patel
Snehal Patel
DMDan M. Meyer
Dan M. Meyer
JSJosef Stehlik
Josef Stehlik

11 November 2021 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
EMEzequiel Molina
Ezequiel Molina
AJAmiti Jain
Amiti Jain
SASara Ahmed
Sara Ahmed
PLPhillip Lam
Phillip Lam
SRSriram Rao
Sriram Rao
FSFarooq Sheikh
Farooq Sheikh
OBJECTIVES: The influence of preoperative left ventricular size in outcomes following centrifugal-flow left ventricular assist device (LVAD) implantation has not been well characterized. METHODS: A cohort of 313 patients who received a centrifugal-flow LVAD at a single institution was analysed. Using a maximally selected log-rank statistic, we investigated whether a left ventricular end-diastolic dimension (LVEDD) cut-off point was associated with worse outcomes. The cohort was then divided in 2 groups based on the LVEDD cut-off point. RESULTS: An LVEDD cut-off point of 59 mm was found to predict worse survival. Smaller LVEDD patients (≤59 mm, N = 52) were older and more likely to have a history of coronary artery disease compared those with a larger LVEDD (>59 mm, N = 261). Smaller LVEDD patients had lower survival compared to larger LVEDD patients (71% vs 85% at 1 year and 58% vs 80% at 2 years, P = 0.003). The need for temporary right ventricular mechanical support was significantly higher in the smaller LVEDD cohort (11.5% vs 1.9%, P = 0.002). Pump flows at time of discharge were lower in the smaller LVEDD group (3.8 vs 4.2 l/min, P = 0.005), who also had a higher incidence of late right ventricular failure (23% vs 12%, P = 0.02), higher rates of gastrointestinal bleeding (0.416 vs 0.256 events per patient-year, P = 0.025) and higher readmissions secondary to low flow alarms (0.429 vs 0.240 events per patient-year, P = 0.007). Multivariable analysis demonstrated that smaller LVEDD, older age, high BUN and high bilirubin levels were independent predictors of worse survival. CONCLUSIONS: In patients receiving a centrifugal-flow LVAD, smaller preoperative LVEDD (≤59 mm) was associated with lower survival and higher incidence of adverse outcomes.

28 July 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
JCJennifer A. Cowger
Jennifer A. Cowger
SSSarah Schettle
Sarah Schettle
FPFrancis D. Pagani
Francis D. Pagani
FSFarooq Sheikh
Farooq Sheikh
JHJennifer M. Hajj
Jennifer M. Hajj
MKManreet K. Kanwar
Manreet K. Kanwar
There is marked variability in device-related (DR) infection frequencies across HeartMate 3 (HM3) centers. The goal is to correlate center driveline (DL) management and infection mitigation practices with DR-infection development, laying foundation for development of best practice recommendations for one facet of HM3 patient care. Coordinators at 30 HM3 centers were surveyed about center practices for infection prophylaxis, intraoperative DL placement and postoperative care, and infection mitigation. Early (≤90 days) and late (>90 day) center DR-infection frequencies were calculated from Society of Thoracic Surgeons Intermacs data linkage. Correlations between center practice patterns and incident DR-infection were examined with multivariable Cox modeling (clustering adjusted hazard ratio [aHR]). Within Intermacs (3,725 patients), 1-year freedom from DR-infection was 87% (80.6-87.3%). Initially, DL dressing changes were performed daily, weekly, and variably at 48%, 21% and 31% of centers. After 4 weeks, 57% deescalated dressing changes to weekly. Chlorhexidine cleanser with a silver-impregnated dressing (Chl-Sil) was standard at 52.7% of programs; 47.3% used chlorhexidine alone or other supplies. Use of Chl-Sil was associated with reduced early (aHR 0.48, p=0.004) and late (aHR 0.64, p=0.02) DR-infection while frequent dressing changes conferred higher late DR-infection (aHR 1.4, p=0.05). Antibiotic prophylaxis, DL tunneling, and diabetes practices did not correlate with DR-infection. Given the burden of DR-infections, best practice recommendations are needed to standardize care. Application of Chl-Sil DL dressings could be a first step in achieving care standardization, while frequent dressing changes following DL incorporation should be avoided.

18 December 2024 in JACC: Heart Failure
Verified
Journal Article
Closed access
EMEzequiel J. Molina
Ezequiel J. Molina
MAMustafa M. Ahmed
Mustafa M. Ahmed
FSFarooq H. Sheikh
Farooq H. Sheikh
JCJoseph C. Cleveland
Joseph C. Cleveland
DGDaniel J. Goldstein
Daniel J. Goldstein
MMMandeep Mehra
Mandeep Mehra